Novavax subsidiary agrees to sell Czech manufacturing campus to Novo Nordisk subsidiary for $200M

NOVAVAX INC

Total purchase price $200M; $10M credit from September 2024 and $10M escrow released 12 months post-closing.
Closing conditioned on Czech drug regulator modifying Novavax CZ's manufacturing authorization to reduce scope.
Novavax CZ continues operations; purchaser reimburses operating costs up to $3.5M per month until closing.
Customary indemnification; termination right if condition not satisfied within 4 months of signing.
Transaction involves transfer of land, equipment, contracts, and employees at Bohumil, Jevany facility.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.